Browsing category:

Respiratory Tract Agent


On July 2, 2015 the FDA announced its approval for the potent duo of Lumacaftor and Ivacaftor to treat patients suffering from Cystic Fibrosis (CF). Coined Orkambi, which is marketed by Vertex Pharmaceuticals, this effectual treatment is specifically approved for patients ages 12 and older who have the homozygous F508 mutation of the CF transmembrane[…]

Read More

GlaxoSmithKline has announced that the FDA has approved fluticasone furoate inhalation powder, as a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as preventative therapy in patients 12 and up. This therapy is only intended to prevent an asthma attack, not to treat it once it happens. For treating an asthma attack, one[…]

Read More

Recently revealed results from a successful Phase 3 study combining Ivacaftor {Kalydeco} and Lumacaftor {VX-809} are extremely positive for patients with a common Cystic Fibrosis {CF} mutation. Patients who have the mutation of Cystic Fibrosis, which entails two copies of the F508del, have demonstrated in Phase 3 clinical trials an effective response to treatment with[…]

Read More

On July 5, 2011, Indacaterol was approved by the FDA for the treatment of chronic obstructive pulmonary disease, or COPD. Novartis announced that the brand name for this device would be the Arcapta Neohaler, and the specific approval for this once daily medication is as a long-acting beta2-adrenergic agonist for the maintenance treatment of airflow[…]

Read More

Ciprofloxacin Hydrochloride, known as the brand name antibiotic Proquin XR, is an effectual fluoroquinolone. Marketed by Depomed, the patent for Proquin XR is set to expire on September 19, 2016. Ciprofloxacin hydrochloride is projected to flourish as a generic antibiotic, due in part to its ease of use as a once daily 500 milligram dose.[…]

Read More

Trandolapril is intended for patients with hypertension, or for anyone who has experienced heart failure post myocardial infarction. Particularly effective for those patients who have left-ventricular dysfunction after a heart attack, trandolapril is an angiotensin-converting enzyme, or ACE inhibitor. Marketed by Abbott as the brand name Mavik, the patent for this lifesaving medication is due[…]

Read More

Patients suffering from debilitating pulmonary arterial hypertension, or PAH, find extensive relief when treated with ambrisentan. Also known as the brand name Letairis, marketed by Gilead, ambrisentan is effectual at preventing the thickening of the blood vessels, particularly those in the heart and lungs. Ambrisentan, CAS number 177036-94-1,  treats the high blood pressure in the[…]

Read More

Olopatadine CAS# 113806-05-6 & Olopatadine Hydrochloride CAS# 140462-76-6, are also known as Patanol and Pataday, which are marketed by Alcon. With the patent for olopatadine due to expire on June 6, 2015, researchers are looking forward to offering generic options of this popular allergy remedy. Olopatadine is effectual as an ophthalmic solution in the form[…]

Read More

Pitavastatin is often recognized by it’s brand name LOVALO, which is marketed by Kowa/Lilly. With the patent for LOVALO due to expire on May 19, 2015, this remarkable statin stands to create quite a stir as a generic product. Approved to treat both primary hyperlipidemia and mixed dyslipidemia, pitavastatin is unique as it offers an[…]

Read More

Carvedilol, CAS# 72956-09-3, is known as the brand name Coreg, which is marketed by GlaxoSmithKline. The patent for Coreg will expire on June 7, 2015, making way for a generic market. As a beta-blocker used to treat hypertension and heart failure, carvedilol is also often prescribed to treat and prevent heart attack symptoms. Carvedilol is[…]

Read More